NeOnc Technologies Announces August 12 Conference Call To Present Topline Phase 2a Results From NEO100-01 Trial Of Intranasal NEO100 In IDH1-Mutant Glioma

Benzinga Newsdesk www.benzinga.com Neutral 84.7%

Neg 0% Neu 84.7% Pos 0%

Comments

No comments yet. Be the first!